Matthew A. Gubens

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Abstract CT281: A phase II trial of ivonescimab for previously treated thymic carcinoma UCLA L-11

  Cancer Research · 2026-04-17

• Non–Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology

  Journal of the National Comprehensive Cancer Network · 2026-04-01 · 5 citations

• Amivantamab Plus Lazertinib in Atypical <i>EGFR</i> -Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2

  Journal of Clinical Oncology · 2025-12-01 · 2 citations

• P1.07.40 Detection of ctDNA Prior to Neoadjuvant Osimertinib Treatment Correlates With Decreased EFS in EGFR-Mutated NSCLC

  Journal of Thoracic Oncology · 2025-10-01 · 1 citations

• NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 7.2025

  Journal of the National Comprehensive Cancer Network · 2025-09-01 · 47 citations

• Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial

  The Lancet Respiratory Medicine · 2025-06-24 · 10 citations

• An international, multicenter, prospective randomized trial of adjuvant chemotherapy for stage Ia-IIa non-small cell lung cancer identified as high-risk by a 14-gene molecular assay.

  Journal of Clinical Oncology · 2025-06-04

• Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology

  Journal of the National Comprehensive Cancer Network · 2025-06-01 · 23 citations

• Abstract 2276: Whole exome sequencing of immune-mediated colitis in cancer patients treated with immune checkpoint inhibitors

  Cancer Research · 2025-04-21

• Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events

  Journal for ImmunoTherapy of Cancer · 2025-03-01 · 7 citations

• Associations of frailty with survival, hospitalization, functional decline, and toxicity among older adults with advanced non-small cell lung cancer

  The Oncologist · 2024-12-09 · 4 citations

• Management of Stage III Non–Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights

  JCO Oncology Practice · 2024-11-18 · 3 citations

• P2.10A.02 Phase 1/1b Trial of MBRC-101, An Anti-EphA5 Monomethyl Auristatin (MMAE) Antibody Drug Conjugate, In Advanced Refractory Solid Tumors

  Journal of Thoracic Oncology · 2024-10-01 · 1 citations

• American Radium Society Appropriate Use Criteria on Cardiac Toxicity Prevention and Management After Thoracic Radiotherapy

  Journal of Thoracic Oncology · 2024-09-21 · 10 citations

• Appropriate Use Criteria (AUC) for the Management of Non-Small Cell Lung Cancer in a Central/Ultra-Central Location: Guidelines from the American Radium Society

  Journal of Thoracic Oncology · 2024-09-11 · 10 citations

• Proceedings of the 1st biannual bridging the gaps in lung cancer conference

  The Oncologist · 2024-09-05 · 1 citations

• Real-World Biomarker Test Ordering Practices in Non–Small Cell Lung Cancer: Interphysician Variation and Association With Clinical Outcomes

  JCO Precision Oncology · 2024-08-01 · 6 citations

• Management of Stage III Non–Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update

  Journal of Clinical Oncology · 2024-07-23 · 36 citations

• Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study

  Journal of Clinical Oncology · 2024-07-19 · 57 citations